NMRA
$1.60
$-0.13 (-7.51%)-7.51%
ClosedLoading chart...
IndexN/A
Market Cap0.30B
Enterprise Value0.11B
Income$-0.07B
Sales$0.00B
EmployeesN/A
P/E-1.20
P/S0.00
P/B2.82
P/C-1.42
EV/EBITDA-0.47
EV/SalesN/A
EPS (ttm)-1.33
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume1.13M
Shs Outstand0.19B
Change-7.51%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $668.00K | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $-668.00K | $0.00 | $0.00 | $0.00 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Expenses | $263.46M | $187.53M | $135.87M | $237.32M | $95.52M |
| Operating Income | $-263.46M | $-188.19M | $-135.87M | $-237.32M | $-95.52M |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Income | $-243.79M | $-235.93M | $-130.90M | $-237.31M | $-99.27M |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS (Basic) | $-1.53 | $-1.49 | $-0.86 | $-1.56 | $-0.65 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $316.97M | $496.19M | $426.23M | $429.30M | $197.95M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $29.91M | $27.12M | $873.08M | $754.52M | $292.33M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $287.06M | $469.08M | $-446.85M | $-325.22M | $-94.38M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $287.06M | $469.08M | $-446.85M | $-325.22M | $-94.38M |
| Total Liabilities & Stockholders Equity | $316.97M | $496.19M | $426.23M | $429.30M | $197.95M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Income | $-243.79M | $-235.93M | $-130.90M | $-237.31M | $-99.27M |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-182.94M | $-163.28M | $-114.90M | $-75.42M | $-26.76M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateGlobeNewswire Inc. NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmBenzinga Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026GlobeNewswire Inc. Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswire Inc. Top 3 Biotech Stocks Capitalizing on the AI RevolutionInvesting.com Neumora Therapeutics to Host Virtual R&D Day on October 27GlobeNewswire Inc. Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025GlobeNewswire Inc. Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861GlobeNewswire Inc.
Show 12 more stories
Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law FirmGlobeNewswire Inc. Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmGlobeNewswire Inc. Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRAGlobeNewswire Inc. NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action LawsuitGlobeNewswire Inc. NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire Inc. NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRAGlobeNewswire Inc. Class Action Lawsuit Reminder (NMRA): Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Investors - A Securities Fraud Class Action Lawsuit Has Been FiledGlobeNewswire Inc. Neumora Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRAGlobeNewswire Inc. SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsGlobeNewswire Inc. ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRAGlobeNewswire Inc. Neumora Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRAGlobeNewswire Inc. NMRA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the Neumora Therapeutics, Inc. (NMRA) Class ActionGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Discover more
You may be interested in